Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Common Equity (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Common Equity readings, the most recent being $1.0 billion for Q1 2026.

  • On a quarterly basis, Common Equity rose 27.5% to $1.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 billion, a 27.5% increase, with the full-year FY2025 number at $954.3 million, up 31.15% from a year prior.
  • Common Equity hit $1.0 billion in Q1 2026 for Catalyst Pharmaceuticals, up from $954.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q1 2026 to a low of $220.2 million in Q1 2022.
  • Median Common Equity over the past 5 years was $561.4 million (2024), compared with a mean of $563.1 million.
  • Biggest five-year swings in Common Equity: rose 23.27% in 2022 and later skyrocketed 89.63% in 2024.
  • Catalyst Pharmaceuticals' Common Equity stood at $300.4 million in 2022, then grew by 29.11% to $387.9 million in 2023, then soared by 87.59% to $727.6 million in 2024, then surged by 31.15% to $954.3 million in 2025, then grew by 6.12% to $1.0 billion in 2026.
  • The last three reported values for Common Equity were $1.0 billion (Q1 2026), $954.3 million (Q4 2025), and $920.2 million (Q3 2025) per Business Quant data.